cell-free DNA testing market is expected to grow steadily at a CAGR of XX% during 2015 to 2022

PUNE, INDIA, January 13, 2017 /EINPresswire.com/ -- Cell-Free DNA (cfDNA) Testing:

Among the Cell-free DNA testing market by test type, the cell-free fetal DNA testing market is dominating the market by occupying a largest share of XX%. The donor DNA product is expected to launch in 2017 hence CAGR is calculated from 2017-20122 which makes it the fastest growing segment with CAGR XX%. In applications, the gynecology holds the largest segment with XX% share and transplantation is the fastest growing segment with a CAGR of XX% from 2017 to 2022. Geographical wise, North America holds the largest market, with a share of XX% followed by Europe and Asia. The APAC region is the fastest growing region with a CAGR of XX% from 2015 to 2022 suggesting an array of opportunities for growth and likely to be getting into the eyes of new investors in the cell-free DNA testing market. Growth in the Asian market is attributed to rising prevalence of diseases related to lifestyle change and government initiatives in establishing innovative technologies and demand for sophisticated medical services.

Request Sample Report @ https://www.wiseguyreports.com/sample-request/502798-cell-free-dna-cfdna-testing-global-market-forecast-to-2022

The cell-free DNA testing market is expected to grow steadily at a CAGR of XX% during 2015 to 2022. The factors driving the growth of this market are raising number of late pregnancies leading to high incidence rates of babies with chromosomal disorders, increasing number of life threatening cancer and infectious diseases are likely to propel the market. In addition, increasing demand for early detection through non-invasive testing procedures, healthy growth with increase in the number of deals by collaborations and acquisitions to open an array of opportunities for the market to flourish are some of the opportunities that are propelling the growth of the market. However, lack of trained health care professionals, ethical issues related to genetic testing, lack of standardization, high cost and non affordability in low- and middle-income countries, unfavourable reimbursement policies and strict legal and regulatory guidelines are hampering the growth of the market. The threats for the Cell-free DNA testing market include the availability of alternative screening methods which will impact the existing market.

The cell-free DNA testing global market is a highly competitive market and all the existing players in this market are involved in developing new and advanced assays to maintain their market shares. The major players in the cell-free DNA testing market include Berry Genomics Co. Ltd (China), BGI (China), Boreal Genomics (U.S), Guardant health, Inc(U.S), Inivata Limited (U.K), Illumina, Inc.(U.S.), Laboratory Corp. of America Holdings (U.S.), Lifecodexx AG (Germany), Natera, Inc. (U.S.), Personal Genome Diagnostics (U.S), Premaitha Health (U.K.), Quest Diagnostics (U.S.), Roche Holdings AG (Switzerland), Sequenom, Inc. (U.S.), Trovagene, Inc (U.S) etc.

The report provides an in depth market analysis of the above mentioned segments across the following regions:
• North America
• Europe
• Asia-Pacific
• Rest of the World (RoW)

Access Report @ https://www.wiseguyreports.com/reports/502798-cell-free-dna-cfdna-testing-global-market-forecast-to-2022

Table of Content

COMPANY PROFILES 173

8.1 BERRY GENOMICS CO. LTD 173
8.1.1 OVERVIEW 173
8.1.2 FINANCIALS 173
8.1.3 PRODUCT PORFOLIO 173
8.1.3.1 BAMBNI TEST 173
8.1.3.2 Next SeqCN500 174
8.1.3.3 cSMART technology 174
8.1.4 KEY DEVELOPMENTS 174
8.1.5 BUSINESS STRATEGY 175
8.1.6 SWOT ANALYSIS 175

8.2 BGI (BGI DIAGNOSTICS) 176
8.2.1 OVERVIEW 176
8.2.2 FINANCIALS 176
8.2.3 PRODUCT PORFOLIO 176
8.2.3.1 NIFTY Test 176
8.2.4 KEY DEVELOPMENTS 177
8.2.5 BUSINESS STRATEGY 177
8.2.6 SWOT ANALYSIS 178

8.3 BIOCEPT, INC. 179
8.3.1 OVERVIEW 179
8.3.2 FINANCIALS 180
8.3.3 PRODUCT PORTFOLIO 181
8.3.4 KEY DEVELOPMENTS 181
8.3.5 BUSINESS STRATEGY 183
8.3.6 SWOT ANALYSIS 184

8.4 CAREDX, INC. 185
8.4.1 OVERVIEW 185
8.4.2 FINANCIALS 186
8.4.3 PRODUCT DESCRIPTION 186
8.4.3.1 Allosure 186
8.4.4 KEY DEVELOPMENTS 187
8.4.5 BUSINESS STRATEGY 188
8.4.6 SWOT ANALYSIS 189

8.5 GUARDANT HEALTH, INC. 190
8.5.1 OVERVIEW 190
8.5.2 FINANCIALS 190
8.5.3 PRODUCT DESCRIPTION 190
8.5.3.1 Guardant 360 190
8.5.4 KEY DEVELOPMENTS 191
8.5.5 BUSINESS STRATEGY 192
8.5.6 SWOT ANALYSIS 193

8.6 ILLUMINA, INC. 194
8.6.1 OVERVIEW 194
8.6.2 FINANCIALS 195
8.6.3 PRODUCT PORTFOLIO 196
8.6.3.1 Verifi noninvasive Prenatal Test 196
8.6.4 KEY DEVELOPMENTS 197
8.6.5 BUSINESS STRATEGY 198
8.6.6 SWOT ANALYSIS 199

8.7 INIVATA LIMITED 200
8.7.1 OVERVIEW 200
8.7.2 FINANCIALS 200
8.7.3 PRODUCT DESCRIPTION 200
8.7.3.1 TAm-Seq 200
8.7.4 KEY DEVELOPMENTS 201
8.7.5 BUSINESS STRATEGY 201
8.7.6 SWOT ANALYSIS 202

8.8 LABORATORY CORP. OF AMERICA HOLDINGS (LABCORP) 203
8.8.1 OVERVIEW 203
8.8.2 FINANCIALS 203
8.8.3 PRODUCT PORTFOLIO 204
8.8.3.1 InformaSeq prenatal test 204
8.8.3.2 Epi proColon test 205
8.8.4 KEY DEVELOPMENTS 205
8.8.5 BUSINESS STRATEGY 207
8.8.6 SWOT ANALYSIS 208

8.9 LIFECODEXX AG 209
8.9.1 OVERVIEW 209
8.9.2 FINANCIALS 209
8.9.3 PRODUCT PORFOLIO 209
8.9.3.1 Prena Test 209
8.9.4 KEY DEVELOPMENTS 210
8.9.5 BUSINESS STRATEGY 210
8.9.6 SWOT ANALYSIS 211

8.10 NATERA, INC. 212
8.10.1 OVERVIEW 212
8.10.2 FINANCIALS 212
8.10.3 PRODUCT PORTFOLIO 213
8.10.3.1 Panorama 213
8.10.3.2 Constellation 213
8.10.4 KEY DEVELOPMENTS 214
8.10.5 BUSINESS STRATEGY 216
8.10.6 SWOT ANALYSIS 217

8.11 PERSONAL GENOME DIAGNOSTICS 218
8.11.1 OVERVIEW 218
8.11.2 FINANCIALS 218
8.11.3 PRODUCT DESCRIPTION 218
8.11.3.1 MetDetect-R 218
8.11.3.2 PlasmaSelect-R 219
8.11.4 KEY DEVELOPMENTS 219
8.11.5 BUSINESS STRATEGY 220
8.11.6 SWOT ANALYSIS 221

8.12 QUEST DIAGNOSTICS 222
8.12.1 OVERVIEW 222
8.12.2 FINANCIALS 223
8.12.3 PRODUCT PORFOLIO 224
8.12.3.1 QNatal Advanced 224
8.12.4 KEY DEVELOPMENTS 224
8.12.5 BUSINESS STRATEGY 226
8.12.6 SWOT ANALYSIS 227

8.13 ROCHE HOLDINGS AG 228
8.13.1 OVERVIEW 228
8.13.2 FINANCIALS 229
8.13.3 PRODUCT PORTFOLIO 230
8.13.3.1 Cobas EGFR mutation test V2 230
8.13.3.2 HARMONY PRENATAL TEST 231
8.13.4 KEY DEVELOPMENTS 231
8.13.5 BUSINESS STRATEGY 233
8.13.6 SWOT ANALYSIS 234

8.14 SEQUENOM, INC. 235
8.14.1 OVERVIEW 235
8.14.2 FINANCIALS 236
8.14.3 PRODUCT PORTFOLIO 237
8.14.3.1 MaterniT GENOME 237
8.14.3.2 MaterniT21 PLUS NIPT 237
8.14.3.3 VisibiliT Prenatal Test 238
8.14.3.4 Sensigene Fetal Rhd Genotyping 238
8.14.4 KEY DEVELOPMENTS 238
8.14.5 BUSINESS STRATEGY 240
8.14.6 SWOT ANALYSIS 241

8.15 TROVAGENE, INC. 242
8.15.1 OVERVIEW 242
8.15.2 FINANCIALS 243
8.15.3 PRODUCT PORTFOLIO 243
8.15.4 KEY DEVELOPMENTS 244
8.15.5 BUSINESS STRATEGY 246
8.15.6 SWOT ANALYSIS 247

…CONTINUED

Buy this Report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=502798

NORAH TRENT
Wise Guy Reports
+91 841 198 5042
email us here